More AIDS patients may get cheaper drugs

(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.

In the first deal of its kind, the pharmaceutical company has agreed to allow four of its to be made by generic companies at a cheaper cost in return for a small proportion of royalties, United Nations said.

Most of the 33 million people worldwide who have HIV, the virus that causes , live in Africa. One of the drugs will also be used to treat people with hepatitis.

The deal was negotiated by the Medicines Patent Pool, part of a U.N.-led partnership that raises money for AIDS, tuberculosis and malaria by things like taxing airplane tickets. Among the partnership's 29 member countries, only Chile, France, Korea, Mali and Niger are actually implementing the airline tax.

"We will continue to work with Gilead and others to expand access to all people living with HIV in developing countries," said Ellen 't Hoen, executive director of the Medicines Patent Pool.

Gilead will receive from three to five percent royalties on its four drugs, which will be supplied to about 100 countries.

Until now, its drugs have been mainly sold in rich countries, and profits from the new deal are expected to be a tiny fraction of those Gilead gets from the West.

Typically, patients in have to wait for years until the patents expire on before they can be made more cheaply by generic companies.

But some experts questioned whether the deal went far enough and pointed out it specifically excludes manufacturers in Thailand and Brazil, which both produce large amounts of .

"This agreement is an improvement over what other big pharma companies are doing to ensure access to their patented AIDS medicines in developing countries," said Michelle Childs, a director at Doctors Without Border's campaign for access to essential medicines. Still, she warned caution was necessary and that the new deal "should not become the template for future agreements."

Other major drugmakers including Johnson and Johnson, Abbott Laboratories and Merck & Co. have so far declined to formally negotiate with the U.N.-led group.

More information:
http://www.unitaid.eu

http://www.msf.org.uk

0 shares

Related Stories

BRICS countries vow to help poor nations in health

date Jul 11, 2011

(AP) -- The world's top emerging countries banded together Monday to help fight diseases in the poorest countries, pledging to explore the transfer of technologies to the developing world to enable poor nations ...

Recommended for you

CDC examines prevalence of undiagnosed HIV

date 21 hours ago

(HealthDay)—Many people have undiagnosed HIV, with the prevalence varying by geographic area, according to a report published in the June 26 issue of the U.S. Centers for Disease Control and Prevention's ...

Potential new HIV therapy seen in immune cells

date Jun 29, 2015

A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The ...

More secondary schooling reduces HIV risk

date Jun 29, 2015

Longer secondary schooling substantially reduces the risk of HIV infection—especially for girls—and could be a very cost-effective way to halt the spread of the virus, according to researchers from Harvard ...

Bill Gates hopeful of AIDS vaccine in 10 years

date Jun 26, 2015

Billionaire and philanthropist Bill Gates, who spends millions of dollars on AIDS drug development, said Friday he hoped for a vaccine against the disease within the next decade as a cure remains far off.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.